Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03339245 · ClinicalTrials.gov registry record · NA
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
A NA study, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03339245 is a NA study that has completed, run by Rockefeller University. The registered enrollment target is 13 participants.
The verdict
NCT03339245, a NA study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease. Fructose ingestion by the American public has steadily increased since the 1980's, and with it increases in NAFLD, fatty liver hepatitis (NASH), diabetes, obesity, and cardiovascular disease. Foods and beverage in the U.S. are typically sweetened with sucrose (50% glucose and 50% fructose) or high fructose corn syrup (45-58% glucose and 42-55% fructose) (Stanhope, et al., 2009). Research into the role that added fructose plays in the emerging chronic health issues is necessary to affect public policy and provide the connection between fructose and the increasing incidence of these co-morbidities. There is evidence that gut bacteria contribute to a range of human diseases including those of the liver and gastrointestinal tract. Dietary fructose has been suggested to play a role in the development of these diseases and has been shown to alter gut microbes in animals. If the investigators find that dietary fructose alters bacteria in the human gut, this would suggest a potential targetable link between high fructose diet and disease.
Interventions
- OTHER Fructose Solution (75 Grams)
- OTHER Glucose Solution (75 grams)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2018-10-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03339245
The ClinicalTrials.gov registry entry for NCT03339245 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fructose Solution (75 Grams) is the first listed.
NCT03339245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03339245 about?
NCT03339245 is a clinical study titled "Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study". Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease. Fructose ingestion by the American public has steadily increased since the 1980's, and with it increases in NAF...
What is the current status of trial NCT03339245?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-12-05. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT03339245?
The interventions under investigation include: Fructose Solution (75 Grams) (OTHER), Glucose Solution (75 grams) (OTHER).
Who is sponsoring clinical trial NCT03339245?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.